NCT02606084View on ClinicalTrials.gov

A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 4, 2015

Primary Completion Date

February 2, 2018

Study Completion Date

February 2, 2018

Conditions

Renal ImpairmentHealthy

Interventions

DRUG

Esketamine

Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.

Trial Locations (2)

Unknown

Miami

Knoxville

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02606084 - A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine | Biotech Hunter | Biotech Hunter